Tag: AbbVie

AbbVie is a pharmaceutical company that discovers, develops and markets both biopharmaceuticals and small molecule drugs. It originated in 2013 as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate into two publicly traded companies. The “new” Abbott Laboratories would specialize in diversified products including medical devices, diagnostic equipment and nutrition products, while AbbVie would operate as a research-based pharmaceutical manufacturer.

Biogen and Abbvie pull their multiple sclerosis drug off the worldwide market

Biogen and AbbVie announced the voluntary withdrawal of ZINBRYTA for relapsing multiple sclerosis. The European Medicines Agency started an urgent review following the reports of eight cases of inflammation of the brain.

AbbVie and Voyager Therapeutics set up a partnership

abbvie office
AbbVie and Voyager Therapeutics entered into a collaboration to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.

AbbVie launches Biologics Manufacturing Facility in Singapore

AbbVie, a global research and development-based biopharmaceutical company, opened its Biologics Manufacturing Facility

AbbVie and Turnstone Biologics starts cooperation on viral immunotherapies

abbvie office
AbbVie and Turnstone Biologics announced a research, option and license agreement whereby AbbVie obtained an option to license up to three of Turnstone's next viral immunotherapies

AbbVie will have to pay $150 million after losing a lawsuit in USA

abbvie office
A federal jury in Chicago on Monday found AbbVie Inc fraudulently misrepresented the risks of its testosterone replacement drug AndroGel

AbbVie and Principia started a collaboration

abbvie office
AbbVie, a global biopharmaceutical company, and Principia Biopharma Inc., a private, clinical-stage biopharmaceutical company, announced today that they have entered a collaboration

AbbVie will announce new data from trials of leukemia drug

AbbVie, a global biopharmaceutical company, announced today that data from multiple clinical trials evaluating venetoclax will be presented at the 22nd European Hematology Association (EHA) Annual Congress

AbbVie’s rheumatoid arthritis drug displayed good results in clinical trial

AbbVie, a global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-NEXT clinical trial evaluating upadacitinib

Clinical studies of cancer drug by AbbVie are unsuccessful

AbbVie, a global biopharmaceutical company, today announced that two Phase 3 studies evaluating veliparib, an investigational, oral poly (adenosine diphosphate -ribose) polymerase (PARP) inhibitor did...